![](/images/graphics-bg.png)
Cost Effectiveness of First-Line Treatment with DoxorubicinIfosfamide Compared to Trabectedin Monotherapy in the Management of Advanced Soft Tissue Sarcoma in Italy, Spain, and Sweden
المؤلفون المشاركون
Panca, Monica
Linch, Mark
Guest, Julian F.
Sladkevicius, Erikas
Gough, Nicholas J.
المصدر
العدد
المجلد 2013، العدد 2013 (31 ديسمبر/كانون الأول 2013)، ص ص. 1-19، 19ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2013-11-03
دولة النشر
مصر
عدد الصفحات
19
التخصصات الرئيسية
الملخص EN
Background.
Doxorubicin/ifosfamide is a first-line systemic chemotherapy for the majority of advanced soft tissue sarcoma (ASTS) subtypes.
Trabectedin is indicated for the treatment of ASTS after failure of anthracyclines and/or ifosfamide; however it is being increasingly used off-label as a first-line treatment.
This study estimated the cost effectiveness of these two treatments in the first-line management of ASTS in Italy, Spain, and Sweden.
Methods.
A Markov model was constructed to estimate the cost effectiveness of doxorubicin/ifosfamide compared to trabectedin monotherapy, defined as the cost per QALY gained, in each country.
Results.
First-line treatment with doxorubicin/ifosfamide resulted in lower two-year healthcare costs and more QALYs than first-line treatment with trabectedin monotherapy in all three countries.
Probabilistic sensitivity analysis showed that at a cost per QALY threshold of €35,000, >90% of a cohort would be cost effectively treated with doxorubicin/ifosfamide compared to trabectedin monotherapy in all three countries.
Conclusion.
Within the model’s limitations, first-line treatment of patients with ASTS with doxorubicin/ifosfamide instead of trabectedin monotherapy affords a cost-effective use of publicly funded healthcare resources in Italy, Spain, and Sweden and is therefore the preferred treatment in all three countries.
These findings support the recommendation that trabectedin should remain a second-line treatment.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Guest, Julian F.& Panca, Monica& Sladkevicius, Erikas& Gough, Nicholas J.& Linch, Mark. 2013. Cost Effectiveness of First-Line Treatment with DoxorubicinIfosfamide Compared to Trabectedin Monotherapy in the Management of Advanced Soft Tissue Sarcoma in Italy, Spain, and Sweden. Sarcoma،Vol. 2013, no. 2013, pp.1-19.
https://search.emarefa.net/detail/BIM-493633
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Guest, Julian F.…[et al.]. Cost Effectiveness of First-Line Treatment with DoxorubicinIfosfamide Compared to Trabectedin Monotherapy in the Management of Advanced Soft Tissue Sarcoma in Italy, Spain, and Sweden. Sarcoma No. 2013 (2013), pp.1-19.
https://search.emarefa.net/detail/BIM-493633
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Guest, Julian F.& Panca, Monica& Sladkevicius, Erikas& Gough, Nicholas J.& Linch, Mark. Cost Effectiveness of First-Line Treatment with DoxorubicinIfosfamide Compared to Trabectedin Monotherapy in the Management of Advanced Soft Tissue Sarcoma in Italy, Spain, and Sweden. Sarcoma. 2013. Vol. 2013, no. 2013, pp.1-19.
https://search.emarefa.net/detail/BIM-493633
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-493633
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)